In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read MoreIn a nutshell This phase 3 trial will investigate the effectiveness of 2 experimental drugs, DS-8201a vs T-DM1, for the treatment of breast cancer (BC). The main outcome will be survival without cancer worsening. The details Breast cancer (BC) is a common and treatable form of cancer. Cancers, including BC, can be categorized depending on certain...
Read More
In a nutshell This trial is examining the safety and effectiveness of pembrolizumab (Keytruda) in the treatment of children and young adults with classical Hodgkin lymphoma (HL). The main outcome to be measured will be a response to treatment. This trial is recruiting in the Republic of Korea and the United States. The details...
Read MoreIn a nutshell This phase 3 trial will investigate the effectiveness of a new drug, DS-8201a, in the treatment of unresectable/metastatic breast cancer (UMBC). The main outcome will be survival without cancer worsening. The details Breast cancer (BC) originates from tissue in the breast. BC is treated with surgery to remove the cancer or...
Read MoreIn a nutshell This trial aims to find out if targeted radiotherapy on the breast in women with low-risk breast cancer after breast-conserving surgery will prevent the cancer from coming back. The main outcome that will be measured is how long it takes before the breast cancer comes back. The study is being conducted in Canada and the United States. The...
Read More
In a nutshell This trial is examining the effectiveness of ibrutinib and obinutuzumab with or without venetoclax in the treatment of older patients with chronic lymphocytic leukemia (CLL). The main outcome to be measured will be survival without cancer worsening. This trial is recruiting in the United States. The details Patients with CLL are often...
Read MoreIn a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive leukemia/lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with...
Read More
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreIn a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of non-Hodgkin lymphoma (NHL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they...
Read More
In a nutshell This study is evaluating the best dose and side effects of mogamulizumab (Poteligeo) plus pembrolizumab (Keytruda) for relapsed or unresponsive lymphoma. The main outcomes to be measured will be the best dose and side effects of treatment, as well as survival without the tumor growing. This study is being conducted in Sacramento,...
Read More
In a nutshell This phase 1 trial is investigating the effectiveness and safety of a new T-cell therapy for relapsed or unresponsive lymphoma. The main outcome to be measured will be the side effects of treatment and long-term survival. This study is being conducted in Chapel Hill, North Carolina, United States. The details In cancer therapy,...
Read MoreIn a nutshell This study will investigate the effects of a new combination of pembrolizumab (Keytruda) and MK-4280 for the treatment of Hodgkin lymphoma (HL). Side effects and response to treatment will be the main effects measured. The details Pembrolizumab and MK-4280 are both targeted therapies for blood cancers. This means that they specifically...
Read More
